Background: The phrase "residual ridge" refers to the morphology of the clinical alveolar ridge after the restoration of bone and soft tissue following tooth extraction. Residual ridge resorption (RRR) is a common and frequently disabling condition, especially in those with edentulous mandibles. There may be a link between osteoporosis and ridge resorption, according to previous studies. We propose a traditional strategy of using Fenugreek bioactive compounds to treat RRR by suppressing inflammation-associated pathways. Objective: This study aimed to evaluate the potential of Fenugreek bioactive compounds as RRR inhibitors. Methods: We conducted an in silico investigation by collecting Fenugreek bioactive compounds using the PubChem database and determining their biological activities using Quantitative Structure-Activity Relationship (QSAR) analysis. The initial target proteins of Fenugreek bioactive compounds were predicted using the Comparative Toxicogenomics Database (CTD). Protein-protein interactions (PPI) were investigated using network analysis in the STRING database and Cytoscape. Results: The findings indicated that Fenugreek bioactive compounds had antioxidant, anti-inflammatory, heme oxygenase 1 (HMOX1) expression enhancing, and tumor necrosis factor (TNF) expression inhibiting properties. Moreover, the PPI network suggested that four bioactive compounds, quercetin, kaempferol, naringenin, and luteolin, interacted with estrogen receptor (ESR)-α/β. Molecular docking studies showed that kaempferol interacted with ESRα (-9.1 kcal/mol) and naringenin bound to ESRβ (-9 kcal/mol). Conclusion: It is concluded that Fenugreek bioactive compounds may be useful for RRR patients. To validate these in silico results, in vivo and in vitro studies need to be performed.